



ABN 11 124 426 339

Level 3, 2-4 Ross Place, South Melbourne, VIC 3205

P +61 (3) 9673 9690 F +61 (3) 9673 9699

www.purifloh.com E corporate@purifloh.com

31 January 2025

ASX Announcement

Quarterly Activities and Cashflow Report for the quarter ending 31 December 2024

During the Quarter ended 31 December 2024 (**the Quarter**) Purifloh (**PO3 or the Company**) achieved key milestones in the advancement of its PFAS destruction technology. The results assisted the Company in securing funding for its key projects whilst expanding its intellectual property portfolio.

Discussions continued with key interested parties, notably Osmoflo and the Department of Defence (DoD).

Research and Development (R&D)

Purifloh progressed its PFAS destruction technology by scaling up activities in preparation for a pilot plant proposal to be assessed by the DoD.

A further workstream is developing applications for treating potable water. The aim is to decontaminate drinking water in remote communities whilst adjusting the process variables to meet much stricter requirements of the Australian Drinking Water Guidelines (ADWG). This process also feeds into ongoing development work on PFAS for the same treatment and has been the recipient of a BRII Grant as set out below.

Relocating to an expanded R&D facility within the CoLabs network supported these developments by providing additional resources and infrastructure for testing and process optimisation.

BRII Grant Announcement

During the Quarter, Purifloh was awarded an initial \$100,000 feasibility grant under the Business Research and Innovation Initiative (BRII): Renewables and Low Emissions Challenge. This initiative supports the development of a renewable energy-powered water treatment system to supply clean drinking water to remote Australian communities.

The study would validate Purifloh's proprietary low-energy advanced oxidation process as a standalone or add-on treatment for potable water. A successful completion of this feasibility demonstration, which is expected by April 2025, could position Purifloh to bid for an additional \$1 million in BRII grant funding to develop a proof-of-concept system.

Intellectual Property (IP)

During the Quarter, Purifloh filed new provisional patent applications related to its PFAS destruction technology aimed to ringfence the versatility and scalability of the technology, both as a standalone solution and in conjunction with existing IP. This positions the Company for future potential licencing of the PFAS destruction technologies as a standalone process or as an add-on to existing onsite solutions.

Next Steps

Looking ahead, Purifloh will continue to build on its achievements with the following priorities:

- Advance preparations for pilot plant proposals, including scaling up PFAS destruction to facilitate larger batch processing.
- Complete the BRII feasibility study and explore opportunities for additional funding through the \$1

million proof-of-concept grant.

- Strengthen its intellectual property portfolio with additional filings and protections to secure its technological leadership.
- Expand collaborations with industry and research partners to accelerate commercialisation.

Corporate

The Company has been active during the Quarter in its efforts to return to trading on the ASX. To that end it notes that:

- All historical outstanding disclosures have been completed and released on the ASX.
- The Company provided a submission to the ASX regarding Listing Rules 12.1 and 12.2.
- The ASX sought clarification on certain issues within that submission, which were provided and released to the market on 6 November 2024.
- A notice of general meeting has since been released on 29 January 2025 that contains resolutions seeking shareholder approval for the issue of new shares in the Company to raise up to \$2m via a placement and to convert the monies owing under its existing debt facility, and accrued fees owed to key management personnel, to equity.
- The Company intends to lodge a prospectus with ASIC in early February 2025, which will also be released to the ASX. The placement shares will be allotted under the Prospectus. Subscriptions in the placement will be accepted subject to the Company receiving shareholder approvals at the general meeting, the Company reaching a minimum subscription of \$1.5m and the Company receiving confirmation from ASX that it will reinstate the Company's shares to official quotation on the ASX.
- The deadline for resumption of trading in the Company's securities prior to its removal from the official list is 15 February 2025. The Company will not meet this deadline, and accordingly, it will apply to ASX for an extension to that deadline. However, there is no certainty that an extension will be granted. The Company will update the market on receipt of ASX's decision.
- Comment on Appendix 4C – Quarterly Cashflow Report
- The Company notes that it has continued to operate on funds drawn down from its Dilato facility. It continues to run the business on the basis of essential expenditure as required and is pleased that it is able to continue to move its R&D activities and commercial outcomes forward with relatively low expenditure.
- The Company drew down an additional \$71,000 during the Quarter and retains its facility through Dilato of approximately \$1.838 million (refer Appendix 4C).
- Funds spent during the Quarter were mainly on R&D costs (\$55,000) by way of staff, rent and equipment.
- \$100,000 was also received from the BRII Grant during the quarter.
- The Company expects further costs to be incurred during the next phase of development.

No payments were made to related parties during the Quarter.

This ASX announcement was authorised and approved by the Chairman of PuriflOH Limited.

For further information:

**Carl Le Souef (Director)
Melbourne, Australia
+ 613 9673 9673**

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Purifloh Limited

ABN

11 124 426 339

Quarter ended ("current quarter")

31 December 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	(55)	(133)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs		
(f) administration and corporate costs	(16)	(57)
1.3 Dividends received (see note 3)		
1.4 Interest received		
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	110	110
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	39	(80)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities		

3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities		
3.5 Proceeds from borrowings	71	188
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	71	188

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	3	5
4.2 Net cash from / (used in) operating activities (item 1.9 above)	39	(80)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	71	188
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of period	113	113

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	113	3
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	113	3

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	3,000	(1,162)
7.2 Credit standby arrangements		
7.3 Other (please specify)		
7.4 Total financing facilities	3,000	(1,162)
7.5 Unused financing facilities available at quarter end		1,838
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	39
8.2 Cash and cash equivalents at quarter end (item 4.6)	113
8.3 Unused finance facilities available at quarter end (item 7.5)	1,838
8.4 Total available funding (item 8.2 + item 8.3)	1,951
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:31 January 2025.....

Authorised by:By the board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.